In 2021, Utah had the highest rate of skin cancer, with an estimated ** people out of 100,000 diagnosed with melanoma or another non-epithelial skin cancer. This statistic shows the incidence rate of skin cancer in the U.S. in 2021, by state, per 100,000 population.

As of 2021, non-Hispanic white people in the United States had the highest incidence rates of skin cancer among all races and ethnicities. Skin cancer is one of the most commonly occurring cancers in the world. Furthermore, the United States is among the countries with the highest rates of skin cancer worldwide. Skin cancer in the U.S. There are a few different types of skin cancer and some are more deadly than others. Basal and squamous skin cancers are more common and less dangerous than melanomas. Among U.S. residents, skin cancer has been demonstrated to be more prevalent among men than women. Skin cancer is also more prevalent among older adults. With treatment and early detection, skin cancers have a high survival rate. Fortunately, in recent years the U.S. has seen a reduction in the rate of death from melanoma. Skin cancer prevention Avoiding and protecting exposed skin from the sun (and other sources of UV light) is the primary means of preventing skin cancer. However, a survey of U.S. adults from 2024 found that around ******* never used sunscreen.

The rate of skin cancer in the United States increased for both sexes from 1999 to 2021, with the rate for males consistently higher than that of females. This statistic shows the incidence rate of skin cancer in the U.S. from 1999 to 2021, by gender, per 100,000 population.

Legacy unique identifier: P00654

Legacy unique identifier: P00647

In 2022, Australia had the fourth-highest total number of skin cancer cases worldwide and the highest age-standardized rate, with roughly 37 cases of skin cancer per 100,000 population. The graph illustrates the rate of skin cancer in the countries with the highest skin cancer rates worldwide in 2022.

In 2021, around 13,883 people aged 70 to 74 years were diagnosed with melanoma of the skin or another non-epithelial skin cancer, the highest number of any age group. This statistic shows the number of new skin cancer cases in the U.S. in 2021, by age.

Skin Cancer Market Outlook

The global skin cancer market size was valued at approximately USD 2.5 billion in 2023 and is projected to reach around USD 4.85 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2032. The market is experiencing steady growth due to factors such as increasing incidence rates of skin cancer, advancements in diagnostic and treatment technologies, and heightened awareness of skin cancer prevention and early detection. As a non-negligible public health concern, skin cancer's rising prevalence continues to drive the demand for effective diagnostic and treatment options, thereby propelling the market forward.

A significant growth factor for the skin cancer market is the increasing incidence of skin cancer cases worldwide. Over the past few years, there has been a noticeable surge in the number of skin cancer diagnoses, which can be attributed to factors such as heightened exposure to ultraviolet (UV) radiation from the sun and tanning beds, aging populations, and cultural trends favoring tanned skin. Additionally, genetic predispositions and the depletion of the ozone layer have further exacerbated the exposure risks. Public health initiatives have increased awareness around protective measures, yet the rise in cases continues, fueling the demand for more advanced diagnostic and treatment solutions.

Technological advancements in the field of dermatology are also significantly contributing to the growth of the skin cancer market. Innovations in diagnostic tools, such as dermatoscopy and advanced imaging solutions, have improved the accuracy and early detection rates of skin cancer. These technologies allow for non-invasive, cost-effective, and efficient identification of skin abnormalities, which are crucial for early intervention and improved patient outcomes. Furthermore, developments in treatment modalities, including targeted therapy and immunotherapy, offer more personalized and effective treatment options, enhancing the demand for cutting-edge solutions in the market.

Increased awareness and initiatives for early detection and prevention are pivotal drivers of market growth. Government bodies and non-profit organizations around the world have launched various campaigns to educate the public on the dangers of UV exposure and the importance of regular skin examinations. These initiatives have led to a rise in the number of individuals seeking medical advice and undergoing skin checks, thereby increasing the demand for dermatological healthcare services. Moreover, as people become more informed about the potential risks and signs of skin cancer, the market for diagnostic and preventive healthcare is expected to grow steadily.

The regional outlook of the skin cancer market indicates significant growth potential across various geographical areas. North America holds a substantial share of the market, driven by a high prevalence of skin cancer, advanced healthcare infrastructure, and robust investment in research and development. Europe follows closely with similar characteristics, including a strong emphasis on research and preventive healthcare measures. The Asia Pacific region is anticipated to exhibit the highest CAGR over the forecast period due to increasing healthcare awareness, rising disposable income, and the growing prevalence of skin cancer in countries such as Australia. Conversely, regions like Latin America, the Middle East, and Africa are expected to witness moderate growth, primarily due to lower awareness levels and limited access to advanced healthcare facilities.

Basal Cell Carcinoma Drug development is a crucial aspect of the skin cancer treatment landscape. As the most common type of skin cancer, basal cell carcinoma (BCC) often requires targeted therapeutic interventions to manage effectively. Recent advancements in pharmacology have led to the creation of innovative drugs that specifically target the molecular pathways involved in BCC proliferation. These drugs offer new hope for patients, particularly those with advanced or recurrent BCC, by providing more effective treatment options with fewer side effects compared to traditional therapies. The ongoing research and development in this area are expected to significantly impact the market, offering patients improved outcomes and expanding the arsenal of available treatments.

Type Analysis

The skin cancer market is segmented by type into basal cell carcinoma, squamous cell carcinoma, and melanoma, each repres

Skin Cancer Diagnostics and Therapeutics Market Outlook

The global skin cancer diagnostics and therapeutics market size was valued at approximately USD 4.2 billion in 2023 and is projected to reach USD 8.9 billion by 2032, expanding at a compound annual growth rate (CAGR) of 8.4% during the forecast period. This steady growth is attributed to several factors including rising skin cancer incidence rates, technological advancements in diagnostic methods, and increasing awareness about early detection and treatment options.

A significant growth factor driving the skin cancer diagnostics and therapeutics market is the increasing prevalence of skin cancer worldwide. Skin cancer remains one of the most common types of cancer, with melanoma and non-melanoma types affecting millions each year. The rise in skin cancer cases is largely attributable to lifestyle factors, such as prolonged exposure to ultraviolet (UV) radiation from the sun and tanning beds, as well as genetic predispositions. Heightened awareness campaigns have also contributed to an increase in the number of diagnosed cases, as people are more likely to seek medical advice for suspicious skin lesions.

Another crucial driver of market growth is the advancement in diagnostic technologies. Innovations such as digital dermatoscopy, artificial intelligence (AI)-based skin lesion analysis, and non-invasive imaging techniques have significantly improved the accuracy and efficiency of skin cancer diagnostics. These advanced methods enable healthcare providers to detect skin cancer at earlier stages, thereby improving patient outcomes. Moreover, the integration of AI in diagnostic procedures is expected to further streamline the process by providing rapid and reliable assessments, which is particularly valuable in regions with limited access to specialized dermatological care.

The expanding therapeutic landscape for skin cancer is also a major growth factor. The development of novel treatments, such as targeted therapies and immunotherapies, has revolutionized the management of skin cancer, particularly for advanced stages of the disease. These therapies offer more personalized treatment options and have shown promising results in improving survival rates. Additionally, the increasing adoption of combination therapies, which utilize multiple treatment modalities, has further enhanced the effectiveness of skin cancer treatment regimens. The continued research and development in this field are likely to yield new therapeutic options, thereby bolstering market growth.

From a regional perspective, North America holds the largest share of the skin cancer diagnostics and therapeutics market, primarily due to high awareness levels, advanced healthcare infrastructure, and significant R&D investments. However, the Asia Pacific region is anticipated to witness the highest growth rate during the forecast period. Factors such as increasing healthcare expenditure, rising incidence of skin cancer, and growing adoption of advanced diagnostic and therapeutic technologies in countries like China and India are expected to drive market expansion in this region.

Type Analysis

When analyzing the market by type, it is imperative to consider the three primary types of skin cancer: basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma. Basal cell carcinoma, being the most common form of skin cancer, accounts for the largest share of the market. This type predominantly affects areas of the skin exposed to the sun and is characterized by its slow growth and low potential to metastasize. The high prevalence of BCC and the availability of multiple treatment options, including surgical excision and topical therapies, contribute to this segment's substantial market share.

Squamous cell carcinoma follows as the second most common type of skin cancer. Unlike BCC, SCC has a higher likelihood of spreading to other parts of the body, making early detection and treatment crucial. The market for SCC diagnostics and therapeutics is driven by the increasing incidence rates, particularly among older adults and individuals with a history of prolonged UV exposure. Advanced diagnostic techniques such as dermatoscopy and imaging, along with effective treatment options like Mohs surgery and radiation therapy, are pivotal in managing SCC, thereby driving market growth in this segment.

Melanoma, despite being less common than BCC and SCC, is the most aggressive form of skin cancer and accounts for a significant portion of the market due to its high mortality rate. The segment is marked by robus

This data was taken from the R `lattice' package. The data is described in the package as follows: These data from the Connecticut Tumor Registry present age-adjusted numbers of melanoma skin-cancer incidences per 100,000 people in Connecticut for the years from 1936 to 1972. Format: A csv file has 37 observations on the following 2 variables. year: years 1936 to 1972. incidence: rate of melanoma cancer per 100,000 population.

The global skin cancer treatment market, valued at $13.82 billion in 2025, is projected to experience robust growth, driven by rising skin cancer incidence rates worldwide, an aging global population increasing susceptibility, and growing awareness regarding early detection and treatment. Technological advancements in diagnostic tools like dermatoscopy and genetic testing, coupled with the development of innovative therapeutic approaches such as immunotherapy and targeted therapy, are significantly contributing to market expansion. The market is segmented by cancer type (melanoma and non-melanoma) and treatment type (diagnosis and therapeutics), with melanoma representing a substantial portion due to its aggressive nature and higher treatment costs. North America currently holds the largest market share, attributed to advanced healthcare infrastructure, high prevalence of skin cancer, and increased spending on healthcare. However, the Asia-Pacific region is expected to witness significant growth in the coming years, driven by rising disposable incomes, increased healthcare awareness, and expanding healthcare infrastructure in developing economies. While effective treatments are available, limitations such as high treatment costs, potential side effects of certain therapies, and lack of access to advanced healthcare in under-resourced regions pose challenges to market growth. The competitive landscape features major pharmaceutical companies and diagnostic providers actively engaged in research and development, further fueling market expansion. The forecast period of 2025-2033 anticipates a continuation of this growth trajectory. The 5.21% CAGR suggests a considerable market expansion, influenced by factors such as ongoing research leading to more targeted and effective treatments, improvements in early detection strategies, and broader access to healthcare in emerging markets. However, the market will continue to navigate challenges like the price sensitivity of certain therapies and the need for sustained investment in research and development to address treatment limitations and enhance patient outcomes. The continued development and adoption of innovative therapies, alongside improvements in diagnostic capabilities, will be key drivers of future market growth. Competition among established players and emerging biotech companies will intensify, further shaping the market landscape in the coming years. Recent developments include: In March 2022, the United States Food and Drug Administration approved nivolumab and relatlimab-rmbw (Opdualag, Bristol-Myers Squibb Company) for adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. Opdualag is a fixed-dose combination of the LAG-3-blocking antibody relatlimab and the programmed death receptor-1 blocking antibody nivolumab., In January 2022, SkinCure Oncology focused on providing a comprehensive model for the delivery of Image-Guided Superficial Radiotherapy (Image-Guided SRT) and launched GentleCure.com, a consumer health education platform offering evidence-based treatment options for basal cell (BCC) and squamous cell skin cancers (SCC).. Key drivers for this market are: Increasing Incidence of Skin Cancer, Rising Awareness About Skin Cancer; Extensive Research and Developments. Potential restraints include: Increasing Incidence of Skin Cancer, Rising Awareness About Skin Cancer; Extensive Research and Developments. Notable trends are: Non-Melanoma by Cancer Type Segment is Expected to Grow Over the Forecast Period.

This csv reports melanoma registration rates, per 100,000 population, by age. Age is grouped in 5 year segments (eg 0–4 years old, 5–9 years old). New Zealand and Australia have the world’s highest rates of melanoma, the most serious type of skin cancer. Melanoma is mainly caused by exposure to ultraviolet (UV) light, usually from the sun. New Zealand has naturally high UV levels, especially during summer.
The risk of developing melanoma is affected by factors such as skin colour and type, family history, and the amount of sun exposure. Melanoma can affect people at any age, but the chance of developing a melanoma increases with age. We report on age-standardised rates of melanoma to account for the increasing proportion of older people in our population. Our data on melanoma registrations come from the New Zealand Cancer Registry and the Ministry of Health's Mortality Collection. The passing of the Cancer Registry Act 1993 and Cancer Registry Regulations 1994 led to significant improvements in data quality and coverage (Ministry of Health, 2013). A sharp increase in registrations after 1993 is likely to have been related to these legislative and regulatory changes; for this reason we have only analysed data from 1996. 2014–15 data are provisional and subject to change. More information on this dataset and how it relates to our environmental reporting indicators and topics can be found in the attached data quality pdf.

In the period from 2014 to 2020, the probability of a person in the U.S. surviving the first five years after being diagnosed with melanoma of the skin when it was confined locally was ** percent. This statistic shows the ********* relative survival rate for melanoma skin cancer in the U.S. from 2014 to 2020, by stage at diagnosis.

Supplementary Figure 1. Cutaneous Melanoma Age-adjusted Incidence Trends (2012-2021) Supplementary Figure 2. Cutaneous Melanoma Age-adjusted Mortality Trends (2013-2022) Journal of the American Academy of Dermatology

Mortality from malignant melanoma (ICD-10 C43 equivalent to ICD-9 172). To reduce deaths from malignant melanoma. Legacy unique identifier: P00646

The incidence of non-melanoma skin cancer is 17-fold lower in Singapore compared to the UK1, despite Singapore receiving 2-3 times more year-round ultraviolet radiation (UV)2,3. The ageing epidermis of the skin comprises competing somatic mutant clones4,5, from which such cancers develop. We question if differences in keratinocyte skin cancer incidence are reflected in the mutational landscape by comparing ageing facial epidermis from donors of Singapore and the UK. We find UK skin to be a highly competitive, densely mutated landscape with 4-fold greater mutation burden compared to Singaporean skin and differences in clonal selection by country. We disproportionately observe multiple features common to keratinocyte skin cancers6,7,8 in UK skin, such as UV mutagenesis, copy number aberration and hotspot mutations (in particular TP53 R248W). We conclude that keratinocyte skin cancer incidence is reflected in the somatic clones of non-cancerous epidermis. Finally, we re-analyse squamous cell carcinoma exomes from Korea9 to show, even in low incidence populations, carcinogenesis is driven by UV damage.

Excess relative risk of skin cancer incidence by cumulative dose from external gamma-rays exposure.

Rate: Number of deaths due melanoma cancer per 100,000 Population.

Definition: Number of deaths per 100,000 with malignant melanoma of the skin as the underlying cause of death (ICD-10 code: C43).

Data Sources:

(1) Centers for Disease Control and Prevention, National Center for Health Statistics. Compressed Mortality File. CDC WONDER On-line Database accessed at http://wonder.cdc.gov/cmf-icd10.html

(2) Death Certificate Database, Office of Vital Statistics and Registry, New Jersey Department of Health

(3) Population Estimates, State Data Center, New Jersey Department of Labor and Workforce Development

For current version see: https://data.sandiegocounty.gov/Health/2021-Non-Communicable-Chronic-Diseases/v7dt-rwpx

Basic Metadata *Rates per 100,000 population. Age-adjusted rates per 100,000 2000 US standard population.

**Blank Cells: Rates not calculated for fewer than 5 events. Rates not calculated in cases where zip code is unknown.

***API: Asian/Pacific Islander. ***AIAN: American Indian/Alaska Native.

Prepared by: County of San Diego, Health & Human Services Agency, Public Health Services, Community Health Statistics Unit, 2019.

Code Source: ICD-9CM - AHRQ HCUP CCS v2015. ICD-10CM - AHRQ HCUP CCS v2018. ICD-10 Mortality - California Department of Public Health, Group Cause of Death Codes 2013; NHCS ICD-10 2e-v1 2017.

Data Guide, Dictionary, and Codebook: https://www.sandiegocounty.gov/content/dam/sdc/hhsa/programs/phs/CHS/Community%20Profiles/Public%20Health%20Services%20Codebook_Data%20Guide_Metadata_10.2.19.xlsx

BackgroundAustralia has one of the highest skin cancer rates in the world. ‘SunSmart’ is a multi-component, internationally recognised community-wide skin cancer prevention program implemented in Melbourne, Australia, since summer 1988–1989. Following recent reductions in melanoma rates among younger Australian cohorts, the extent of behaviour change and the potential contribution of prevention programs to this decline in melanoma rates are of interest. Sun protection is a multifaceted behaviour. Measures previously applied to monitor change over time in preventive behaviour for this population focused on individual behaviours. The omission of multiple behaviours that reduce exposure to ultraviolet radiation (UV) may have led to underestimates of behaviour change, meriting further analysis of long-term trends to contribute to this debate.Methods and findingsA population-based survey was conducted in Melbourne in the summer before SunSmart commenced (1987–1988) and across summers in 3 subsequent decades (1988–2017). During summer months, residents (14–69 years) were recruited to cross-sectional weekly telephone interviews assessing their tanning attitudes, sun protection behaviour, and sunburn incidence on the weekend prior to interview. Quotas were used to ensure the sample was proportional to the population by age and sex, while younger respondents were oversampled in some years. The majority of the respondents reported their skin was susceptible to sunburn. Changes in sun protection behaviour were analysed for N = 13,285 respondents in multivariable models, cumulating surveys within decades (1987–1988: N = 1,655; 1990s: N = 5,258; 2000s: N = 3,385; 2010s: N = 2,987) and adjusting for relevant ambient weather conditions and UV levels on weekend dates. We analysed specific and composite behaviours including a novel analysis of the use of maximal sun protection, which considered those people who stayed indoors during peak UV hours together with those people well-protected when outdoors. From a low base, use of sun protection increased rapidly in the decade after SunSmart commenced. The odds of use of at least 1 sun protection behaviours on summer weekends was 3 times higher in the 1990s than pre-SunSmart (adjusted odds ratio [AOR] 3.04, 95% CI 2.52–3.68, p